Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals raised $500 million via a stock offering at $35.50/share to fund avexitide’s path toward a potential 2027 launch. In its Phase 3 Lucidity trial, avexitide cut serious hypoglycemic events by 55% vs placebo, with the data needed for an FDA submission by year-end. Despite dilution and a 247% YTD rally, analysts estimate peak U.S. sales of ~$1.5B, supporting a cautious “buy on pullbacks” view after run-up.

Analysis

AMLX now has a cleaner balance sheet, but the real market implication is that financing risk has shifted from existential to execution risk. That usually supports a higher floor for the equity, yet it also removes part of the “distress optionality” that drove earlier upside, so the stock can still de-rate if investors decide the 2027 cash-flow bridge is too long for a fully priced story. The offering also creates a near-term supply overhang: new holders are likely to treat this as a tradable biotech catalyst, not a long-duration core position.

The key second-order effect is that this becomes a commercial-launch story, not just a clinical one. If avexitide advances, the bottleneck is likely payer adoption and prescribing behavior in a narrow endocrine niche, where peak sales assumptions can look generous on paper and then compress quickly if diagnosis rates, persistence, or prior-auth friction disappoint. The biggest losers are momentum buyers chasing a multibagger after the raise; the biggest beneficiaries are existing shareholders who now have reduced dilution risk and a funded path through regulatory milestones.

Contrarian view: the market may be overreacting to the binary “phase 3 success” headline and underweighting timing. A 2027 launch implies multiple quarters of non-revenue execution, so the stock can stay volatile and expensive long before any commercial proof emerges. The thesis is most vulnerable if FDA filing slips, if the approval label narrows, or if the post-offering float leads to repeated supply at/above the placement price rather than scarcity-driven upside.

Key Decisions for Investors

• Do not chase AMLX here; wait for a retracement toward $28-$30 to establish a starter long, where the risk/reward is better and the dilution overhang is more likely priced in.
• If already long AMLX, trim into strength above the $35.50 financing level and use a 1-3 month put spread as a hedge against post-offering digestion and valuation compression.
• For event-driven exposure, consider a small Jan-2026 or Jan-2027 call spread only if AMLX reclaims and holds the offering price for several sessions; otherwise implied upside is too dependent on a far-dated regulatory path.
• Watch the FDA filing cadence as the next catalyst; if submission slips beyond year-end, reassess the bull case immediately because the stock is likely discounting a clean regulatory timeline.
• No broad biotech pair is compelling yet; if you want to express the view, a relative-value short in AMLX against a basket of profitable biotech or broader XBI strength is cleaner than an outright naked short, but only after a failed breakout.